Want to see KR:006280 full AI Analyst Report?
GC Biopharma Corp. (006280) AI Stock Analysis
GC Biopharma Corp.
(Korea Exchange:006280)
The score is primarily constrained by weakened financial performance, with losses and a TTM revenue decline, though this is partly supported by a meaningful rebound to positive operating and free cash flow. Technical signals are neutral-to-mildly constructive short term but remain weaker versus the 200-day trend, and valuation is pressured by the lack of earnings (negative P/E) despite a modest dividend yield.
GC Biopharma Corp. (006280) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- KRW 1.49T
- Dividend Yield
- 1.15%
- Average Volume (3M)
- 24.54K
- Price to Earnings (P/E)
- -29.8
- Beta (1Y)
- 0.20
- Revenue Growth
- 9.73%
- EPS Growth
- -167.75%
- Country
- KR
- Employees
- 2,351
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
GC Biopharma Corp. Business Overview & Revenue Model
Company Description
GC Biopharma Corp. is a pharmaceutical enterprise primarily involved in the production and distribution of various medical products. Its extensive portfolio encompasses specialized treatments for blood-related conditions, non-prescription remedies, g...
GC Biopharma Corp. Financial Statement Overview
Summary
Income statement quality is weak (revenue down TTM and profitability has deteriorated into recurring losses), partially offset by constructive cash-flow momentum (TTM operating and free cash flow turned positive) and a still-serviceable balance sheet despite rising leverage and negative returns.
Income Statement
44NeutralBalance Sheet
56NeutralCash Flow
62Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.96T | 1.99T | 1.68T | 1.63T | 1.71T | 1.54T |
| Gross Profit | 495.82B | 536.00B | 481.93B | 484.63B | 581.80B | 520.59B |
| EBITDA | 141.28B | 155.46B | 80.36B | 109.81B | 187.32B | 159.43B |
| Net Income | -49.90B | -4.67B | -26.28B | -26.63B | 65.45B | 123.21B |
Balance Sheet | ||||||
| Total Assets | 2.82T | 2.97T | 2.74T | 2.64T | 2.53T | 2.46T |
| Cash, Cash Equivalents and Short-Term Investments | 44.66B | 50.80B | 24.00B | 55.51B | 112.31B | 202.94B |
| Total Debt | 938.85B | 982.14B | 828.14B | 724.02B | 575.54B | 606.57B |
| Total Liabilities | 1.49T | 1.58T | 1.26T | 1.10T | 958.90B | 962.39B |
| Stockholders Equity | 1.24T | 1.22T | 1.25T | 1.30T | 1.33T | 1.27T |
Cash Flow | ||||||
| Free Cash Flow | 72.64B | 27.10B | -95.85B | -131.46B | 24.46B | 2.44B |
| Operating Cash Flow | 184.28B | 99.46B | -53.46B | -5.47B | 119.15B | 125.98B |
| Investing Cash Flow | -98.31B | -186.65B | -67.89B | -150.24B | -205.26B | -132.08B |
| Financing Cash Flow | -136.74B | 111.44B | 93.85B | 100.51B | -2.48B | -41.27B |
GC Biopharma Corp. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:006280, the sentiment is Positive. The current price of 130200.00 is above the 20-day moving average (MA) of 129370.00, above the 50-day MA of 127240.00, and below the 200-day MA of 137592.36, indicating a neutral trend. The MACD of 1239.76 indicates Negative momentum. The RSI at 53.38 is Neutral, neither overbought nor oversold. The STOCH value of 37.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KR:006280.
GC Biopharma Corp. Peers Comparison
Overall Rating
KR:06962061Neutral
KR:18575057Neutral
KR:06876054Neutral- KR:00628054Neutral
KR:00942044Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| KR:069620 | 61Neutral | KRW 1.16T | 5.95 | ― | 0.59% | 9.87% | 160.28% |
| KR:185750 | 57Neutral | KRW 831.41B | 10.46 | ― | 0.79% | 7.15% | 29.88% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| KR:068760 | 54Neutral | KRW 1.59T | 130.86 | ― | 0.42% | 13.88% | 29.24% |
| KR:006280 | 54Neutral | KRW 1.49T | -29.78 | ― | 1.15% | 9.73% | -167.75% |
| KR:009420 | 44Neutral | KRW 1.90T | -87.32 | ― | ― | 5.00% | -1062.27% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KR:006280 | GC Biopharma Corp. | 130200.00 | 798.34 | 0.62% | |
| KR:009420 | Hanall Biopharma Co., Ltd. | 37500.00 | -1850.00 | -4.70% | |
| KR:068760 | Celltrion Pharm Inc. | 36650.00 | -26478.69 | -41.94% | |
| KR:069620 | Daewoong Pharmaceutical Co., Ltd. | 101100.00 | -41905.73 | -29.30% | |
| KR:185750 | Chong Kun Dang Pharmaceutical Corp. | 63100.00 | -19812.28 | -23.90% | |
| KR:195940 | HK inno.N Corporation | 34250.00 | -15463.16 | -31.10% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026